SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-053940
Filing Date
2024-05-07
Accepted
2024-05-07 07:20:26
Documents
54
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q prld-20240331.htm   iXBRL 10-Q 1140480
2 EX-31.1 prld-ex31_1.htm EX-31.1 15526
3 EX-31.2 prld-ex31_2.htm EX-31.2 15536
4 EX-32.1 prld-ex32_1.htm EX-32.1 8551
5 EX-32.2 prld-ex32_2.htm EX-32.2 8683
  Complete submission text file 0000950170-24-053940.txt   5721935

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT prld-20240331.xsd EX-101.SCH 948252
57 EXTRACTED XBRL INSTANCE DOCUMENT prld-20240331_htm.xml XML 1004668
Mailing Address 175 INNOVATION BOULEVARD WILMINGTON DE 19805
Business Address 175 INNOVATION BOULEVARD WILMINGTON DE 19805 (302) 467-1280
Prelude Therapeutics Inc (Filer) CIK: 0001678660 (see all company filings)

IRS No.: 811384762 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39527 | Film No.: 24919603
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)